PUBLICATIONS

Primary Articles

Robinson M, Gilbert SF, Waters JA, Lujano-Olazaba O, Lara J, Alexander LJ, Green SE, Burkeen GA, Patrus O, Sarwar Z, Holmberg R, Wang C, House CD. Characterization of SOX2, OCT4 and NANOG in Ovarian Cancer Tumor-Initiating Cells. Cancers (Basel). 2021 Jan 12;13(2):262. doi: 10.3390/cancers13020262. PMID: 33445692; PMCID: PMC7828139.

 

​Harrington BS, Ozaki MK, Caminear MW, Hernandez LF, Jordan E, Kalinowski NJ, Goldlust IS, Guha R, Ferrer M, Thomas C, Shetty J, Tran B, Wong N, House CD, and Annunziata CM. Drugs Targeting Tumor-initiating cells prolong survival in a post-surgery, post-chemotherapy ovarian cancer relapse model. Cancers (Basel). 2020 Jun 21;12(6):1645.doi:10.3390/cancers12061645

House CD, Grajales V, Ozaki M, Jordan EA, Wubneh H, Kimble D, James J, Kim M, and Annunziata CM. IKKe cooperates with either MEK or non-canonical NF-kB driving growth of triple-negative breast cancer cells in different contexts. BMC Cancer. 2018 May 25;18(1):595. doi: 10.1186/s12885-018-4507-2

House CD, Jordan EA, Hernandez L, Ozaki M, James JM, Kim MK, Kruhlak MJ, Batchelor E, Elloumi F, Cam MC, and Annunziata CM. NF-kB promotes ovarian tumorigenesis via classical pathways supporting proliferative cancer cells and alternative pathways supporting ALDH+ cancer stem-like cells. Cancer Res. 2017;77(24):6927-40. doi:10.1158/0008-5472.CAN-17-0366

Kim MK, Pongas G, Min DJ, House CD, Jordan EA, Caplen N, Chakka S, Ohiri J, Kruhlak MJ, and Annunziata CM. BRD4 facilitates DNA damage response and represses CBX5/Heterochromatin protein 1 (HP1). Oncotarget. 2017 May 3;8(31):51402-51415. doi: 10.18632/oncotarget.17572

Kim MK, Caplen N, Chakka S, Hernandez L, House CD, Pongas G, Jordan E, Annunziata CM. Identification of therapeutic targets applicable to clinical strategies in ovarian cancer. BMC Cancer. 2016; 16:678

Hernandez L, Kim MK, Lyle LT, Bunch KP, House CD, Ning F, Noonan AM, and Annunziata CM. Characterization of ovarian cancer cell lines as in vivo models for preclinical studies. Gynecol Oncol. 2016:142(2): 332-40

House CD, Wang B, Cennicola K, Williams R, Samaan M, Olender J, Patel V, Baptista-Hon D, Annunziata CM, Gutkind JS, Hales TG, and Lee NH. Voltage-gated Na+ Channel Activity Increases Colon Cancer Transcriptional Activity and Invasion Via Persistent MAPK Signaling. Scientific Reports. 2015; 5:11541 10.1038/srep11541

House CD, Vaske CJ, Schwartz AM, Obias V, Frank B, Luu T, Sarvazyan N, Strausberg RL, Hales TG, Stuart JM and Lee NH. Voltage-gated Na+ channel SCN5A is a key regulator in a colon cancer invasion gene transcriptional network. Cancer Research. 2010;70(17): 6957-6967. *Article featured on issue cover

Zhang J, Panicker LM, Seigneur EM, Lin L, House CD, Morgan W, Chen WC, Mehta H, Haj-Ali M, Yu Z, and Simonds WF. Cytoplasmic polyadenylation element binding protein is a   conserved target of tumor suppressor HRPT2/CDC73. Cell Death and Differentiation. 2010;17(10): 1551-1565

Vaske CJ, House CD, Frank B, Yeang CH, Lee NH and Stuart JM. A factor graph nested effects model to identify networks from genetic perturbations. PLOS Comput.Biol. 2009; 5: e1000274. PMCID:PMC2613752

Tapocik JD, Letwin NE, Kafkafi N, Mayo C, Frank B, Luu TV, Achinike O, House CD, Williams R, Elmer GI, and Lee NH. Identification of candidate genes and gene networks specifically associated with analgesic tolerance to morphine. J. Neurosci. 2009;29: 5295-5307

Lee NH, Haas BJ, Letwin NE, Frank BC, Luu TV, Sun Q, House CD, Yerga-Woolwine S, Farms P, Manickavasagam E, and Joe B. Cross-talk of expression quantitative trait loci within 2 interacting blood pressure quantitative trait loci. Hypertension. 2007;50(6): 1126-1133

Review and Method Articles

House CD, Hernandez L, Annunziata CM. In vitro enrichment of ovarian cancer tumor-initiating cells. JoVE. Feb. 18 2015;(96)

House CD, Hernandez L, Annunziata CM. Recent technological advances in using mouse models to study ovarian cancer. Review. Frontiers Oncology. Feb 13 2014;4:26

 

Book Chapters

Waters JW and House CD. Ovarian Cancer Stem Cell Biology and Chemoresistance. In G. Samimi and C. Annunziata (Eds.), Overcoming Ovarian Cancer Chemoresistance (Vol. 11,1st ed. pp. 55-77)